Online inquiry

IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5030MR)

This product GTTS-WQ5030MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets GLP1R gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Heloderma suspectum
RefSeq NM_002062.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2740
UniProt ID P43220
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5030MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8059MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA h2H12ec
GTTS-WQ11655MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ13134MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-04360365
GTTS-WQ12229MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ172MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ3026MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ2096MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AIN457
GTTS-WQ7139MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FG-3019
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW